The valve may now be used to replace failing heart valves previously implanted in high risk patients, according to the report. Clinicians place the Sapein 3 valve into the failing valve through a blood vessel or small incision in the patient’s chest, which offers a less invasive treatment option than repeat open heart surgery.
The FDA originally approved the valve as a replacement for a patient’s natural valve when open heart surgery is deemed too risky.
More articles on supply chain:
Premier: 9 policy recommendations to fix high drug costs
6 FDA decisions to keep an eye on in June
Eli Lilly CFO to retire at year-end
